Sugar-Free Sweetener Sorbitol Could Be Fueling Fatty Liver Disease in Disguise

Sorbitol has long been considered a benign alternative to sugar: it barely moves the blood glucose needle, appears naturally in apples and pears, and fills the shelves of products aimed at people with diabetes. But new research published in Science Signaling raises an unsettling possibility that the sweetener may, under the wrong gut conditions, behave almost exactly like fructose, one of the most metabolically disruptive sugars known. The findings are preliminary and come primarily from zebrafish models, but the mechanism they describe is specific enough to take seriously.

Sorbitol's Hidden Conversion into Fructose in the Liver

The core discovery, from biochemist Dr. Gary Patti's lab at Washington University in St. Louis, is that sorbitol is, in Patti's own words, "one transformation away from fructose" and can induce similar metabolic effects. In a healthy gut, bacteria degrade dietary sorbitol before it gets far enough to cause trouble. But when those bacteria are depleted or overwhelmed, sorbitol passes through the intestinal wall and travels to the liver. There, it is converted into fructose 1-phosphate, a compound that ramps up glycolytic activity and drives fat accumulation, the hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD), the condition formerly and more widely known as non-alcoholic fatty liver disease.

The research team's zebrafish experiments, detailed at Washington University's research hub, showed that depleting gut bacteria with antibiotics produced fatty liver in zebrafish eating a completely normal diet. High dietary doses of sorbitol alone replicated the same liver damage. Reintroducing specific sorbitol-degrading bacteria from the genus Aeromonas reversed the fat accumulation. Blocking the enzyme that converts glucose to sorbitol in the first place, using a drug called epalrestat, also prevented the liver changes. Together, those four lines of evidence point to a coherent chain from sweetener to liver fat.

Why the 30% of Adults with Fatty Liver Disease Should Pay Attention

MASLD already affects an estimated 30% of adults worldwide, and its prevalence has climbed even as public health messaging has pushed people away from sugary drinks toward "diet" alternatives. One persistent puzzle is why fatty liver is so common even among people who seem to be avoiding traditional sugar. This research offers a plausible mechanism: intestinal cells can convert ordinary dietary glucose into sorbitol, particularly at high blood glucose levels. For people with diabetes or prediabetes, who chronically run higher blood glucose, that conversion may be more frequent, meaning sorbitol can accumulate even without consuming a single sugar-free product.

That detail reframes the risk. It is not just about reading ingredient labels. It suggests that metabolic state itself, specifically elevated blood glucose, could determine whether sorbitol becomes a problem. A broader literature review on sweeteners and non-alcoholic fatty liver disease has flagged the need for more human data on exactly these kinds of sweetener-to-liver pathways, and this new work provides a mechanistic candidate worth investigating. Separately, research on artificially sweetened beverage consumption and NAFLD risk in US adults found that exclusive intake of artificially sweetened drinks was significantly associated with increased liver disease risk, suggesting the assumption that "no sugar" means "no liver risk" has needed scrutiny for some time.

How Zebrafish Experiments Isolated Gut Bacteria as the Key Variable

The team's approach was methodical. Using zebrafish as a model organism, they first established baseline liver health, then depleted gut bacteria using antibiotics and watched fatty liver develop on a normal diet. They next administered high-dose sorbitol directly and observed the same outcome, ruling out confounding dietary factors. The critical mechanistic step came when they tracked sorbitol's fate through the gut-liver axis: in the absence of degrading bacteria, sorbitol arrived at the liver intact and was phosphorylated into fructose 1-phosphate, increasing glycolytic flux and fat synthesis. Reintroducing Aeromonas bacteria that actively break down sorbitol restored liver health. Blocking sorbitol production upstream with epalrestat had the same protective effect.

Noteworthy is the enzyme detail: the protein that converts glucose to sorbitol has a low affinity for glucose, meaning it only operates efficiently at elevated glucose concentrations. That biochemical threshold helps explain why the pathway may be especially active in hyperglycemic individuals.

Open Questions About Dose, Gut Diversity, and Human Applicability

The researchers are explicit about what the data do not yet show. Zebrafish share important metabolic pathways with mammals, but they are not humans. The gut microbiome in zebrafish is far less complex than the human version, and the Aeromonas species prominent in zebrafish guts may play a different quantitative role in human intestines. There is also a dose-dependency caveat worth noting: the study's authors state that regular, low-level sorbitol consumption is not likely to cause harm. The effects appeared at high dietary doses and under conditions of microbiome depletion, scenarios that may be more relevant to people who have recently taken broad-spectrum antibiotics, have inflammatory bowel conditions, or consume large amounts of sorbitol-containing products regularly.

The question of what "high dose" means in human equivalents has not yet been answered, and no human clinical data exist for this specific pathway.

What Could Come Next for Sorbitol Research and Diabetes Nutrition

Epalrestat, the drug used to block sorbitol formation in the zebrafish experiments, is already approved in several countries for diabetic neuropathy, where excess sorbitol in nerve tissue is part of the disease mechanism. That existing safety profile makes it a plausible candidate for further investigation as a hepatoprotective agent in high-risk metabolic populations, though that application remains speculative at this stage. More immediately, the findings argue for human cohort studies examining whether microbiome composition moderates the relationship between sorbitol intake and liver fat in people with type 2 diabetes.

For the present, the takeaway is not that anyone should panic about the sorbitol in a stick of sugar-free gum. It is that the assumption underpinning much of diabetic food marketing, that sugar alcohols are metabolically inert, is looking increasingly fragile as researchers probe the gut-liver axis more carefully.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• All experiments were conducted in zebrafish; direct applicability to humans has not yet been established.
• Funding sources were not disclosed in the available article information.
• The harmful effect appears dose-dependent — researchers note that regular, low-level sorbitol consumption is unlikely to cause harm.
• This is a single study and has not yet been independently replicated.

Preclinical study conducted entirely in zebrafish models. Identifies a specific gut-microbiome-dependent mechanism linking dietary sorbitol to hepatic fat accumulation, with named bacterial species (Aeromonas) and a defined metabolic pathway (sorbitol → fructose 1-phosphate). Demonstrates association and proposed causation within an animal model; translation to human physiology remains unconfirmed, and independent replication has not yet been reported.

References

1. (2026). The Sweetener Marketed to Diabetics May Be Silently Harming Their Livers. New Research … https://doi.org/10.1126/scisignal.ado6561
2. Alternative sweetener sorbitol linked to liver disease – The Source – WashU. source.wustl.edu. https://source.wustl.edu/2025/11/alternative-sweetener-sorbitol-linked-to-liver-disease/
3. Konstantinos Kakleas, Foteini Christodouli, Kyriaki Karavanaki (2020). Nonalcoholic fatty liver disease, insulin resistance, and sweeteners: a literature review. Expert Review of Endocrinology & Metabolism. https://doi.org/10.1080/17446651.2020.1740588
4. Tung-Sung Tseng, Wei-Ting Lin, Peng-Sheng Ting, et al. (2023). Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Nutrients. https://doi.org/10.3390/nu15183997
5. Madelyn M. Jackstadt, Ronald Fowle-Grider, Mun-Gu Song, et al. (2025). Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria. Science Signaling. https://doi.org/10.1126/scisignal.adt3549